SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-002956
Filing Date
2022-03-07
Accepted
2022-03-07 07:00:36
Documents
13
Period of Report
2022-03-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20220307.htm   iXBRL 8-K 56094
2 EX-99.1 kalv-ex99_1.htm EX-99.1 21278
  Complete submission text file 0000950170-22-002956.txt   200113

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20220307.xsd EX-101.SCH 2495
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20220307_lab.xml EX-101.LAB 13448
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20220307_pre.xml EX-101.PRE 9939
7 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20220307_htm.xml XML 4720
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 22716189
SIC: 2834 Pharmaceutical Preparations